Literature DB >> 24569453

Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance.

Camilla Jandus, Kayluz Frias Boligan, Obinna Chijioke, He Liu, Meike Dahlhaus, Thomas Démoulins, Christoph Schneider, Marc Wehrli, Robert E Hunger, Gabriela M Baerlocher, Hans-Uwe Simon, Pedro Romero, Christian Münz, Stephan von Gunten.   

Abstract

Alteration of the surface glycosylation pattern on malignant cells potentially affects tumor immunity by directly influencing interactions with glycan-binding proteins (lectins) on the surface of immunomodulatory cells. The sialic acid-binding Ig-like lectins Siglec-7 and -9 are MHC class I-independent inhibitory receptors on human NK cells that recognize sialic acid-containing carbohydrates. Here, we found that the presence of Siglec-9 defined a subset of cytotoxic NK cells with a mature phenotype and enhanced chemotactic potential. Interestingly, this Siglec-9+ NK cell population was reduced in the peripheral blood of cancer patients. Broad analysis of primary tumor samples revealed that ligands of Siglec-7 and -9 were expressed on human cancer cells of different histological types. Expression of Siglec-7 and -9 ligands was associated with susceptibility of NK cell-sensitive tumor cells and, unexpectedly, of presumably NK cell-resistant tumor cells to NK cell-mediated cytotoxicity. Together, these observations have direct implications for NK cell-based therapies and highlight the requirement to consider both MHC class I haplotype and tumor-specific glycosylation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24569453      PMCID: PMC3973073          DOI: 10.1172/JCI65899

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  54 in total

1.  Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28-/- mice.

Authors:  S Maier; C Tertilt; N Chambron; K Gerauer; N Hüser; C D Heidecke; K Pfeffer
Journal:  Nat Med       Date:  2001-05       Impact factor: 53.440

2.  A small region of the natural killer cell receptor, Siglec-7, is responsible for its preferred binding to alpha 2,8-disialyl and branched alpha 2,6-sialyl residues. A comparison with Siglec-9.

Authors:  Toshiyuki Yamaji; Takane Teranishi; Magnus S Alphey; Paul R Crocker; Yasuhiro Hashimoto
Journal:  J Biol Chem       Date:  2001-12-10       Impact factor: 5.157

3.  CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells.

Authors:  R Jacobs; G Hintzen; A Kemper; K Beul; S Kempf; G Behrens; K W Sykora; R E Schmidt
Journal:  Eur J Immunol       Date:  2001-10       Impact factor: 5.532

4.  Comparative studies of human FcRIII-positive and negative natural killer cells.

Authors:  A Nagler; L L Lanier; S Cwirla; J H Phillips
Journal:  J Immunol       Date:  1989-11-15       Impact factor: 5.422

5.  Binding specificity of siglec7 to disialogangliosides of renal cell carcinoma: possible role of disialogangliosides in tumor progression.

Authors:  A Ito; K Handa; D A Withers; M Satoh; S Hakomori
Journal:  FEBS Lett       Date:  2001-06-01       Impact factor: 4.124

6.  Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo.

Authors:  C Y Koh; B R Blazar; T George; L A Welniak; C M Capitini; A Raziuddin; W J Murphy; M Bennett
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

7.  Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and -independent mechanisms.

Authors:  Gavin Nicoll; Tony Avril; Kevin Lock; Koichi Furukawa; Nicolai Bovin; Paul R Crocker
Journal:  Eur J Immunol       Date:  2003-06       Impact factor: 5.532

Review 8.  Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis.

Authors:  Reiji Kannagi; Mineko Izawa; Tetsufumi Koike; Keiko Miyazaki; Naoko Kimura
Journal:  Cancer Sci       Date:  2004-05       Impact factor: 6.716

9.  Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy.

Authors:  K Kärre; H G Ljunggren; G Piontek; R Kiessling
Journal:  Nature       Date:  1986 Feb 20-26       Impact factor: 49.962

10.  Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism.

Authors:  H G Ljunggren; K Kärre
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

View more
  137 in total

Review 1.  Regulation of airway inflammation by Siglec-8 and Siglec-9 sialoglycan ligand expression.

Authors:  Robert P Schleimer; Ronald L Schnaar; Bruce S Bochner
Journal:  Curr Opin Allergy Clin Immunol       Date:  2016-02

2.  Stage-specific requirement of kinase PDK1 for NK cells development and activation.

Authors:  Junming He; Yuande Wang; Tian Liu; Guangao Liu; Shasha Chen; Qiaozhen Li; Yuhe Quan; Haoyan Yang; Jin Feng; Song Wang; Meixiang Yang; Zhongjun Dong
Journal:  Cell Death Differ       Date:  2019-01-08       Impact factor: 15.828

3.  Protein-glycan interactions as targets of intravenous/subcutaneous immunoglobulin (IVIg/SCIg) preparations.

Authors:  S von Gunten
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

4.  Antibody repertoire profiling with mimotope arrays.

Authors:  Shina Pashova; Christoph Schneider; Stephan von Gunten; Anastas Pashov
Journal:  Hum Vaccin Immunother       Date:  2016-12-08       Impact factor: 3.452

5.  SAMP-ending down sepsis.

Authors:  Alison Coady; Victor Nizet
Journal:  Ann Transl Med       Date:  2016-12

6.  The human IgG anti-carbohydrate repertoire exhibits a universal architecture and contains specificity for microbial attachment sites.

Authors:  Christoph Schneider; David F Smith; Richard D Cummings; Kayluz Frias Boligan; Robert G Hamilton; Bruce S Bochner; Sylvia Miescher; Hans-Uwe Simon; Anastas Pashov; Tchavdar Vassilev; Stephan von Gunten
Journal:  Sci Transl Med       Date:  2015-01-07       Impact factor: 17.956

Review 7.  Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design.

Authors:  Donella M Beckwith; Maré Cudic
Journal:  Semin Immunol       Date:  2020-01-09       Impact factor: 11.130

Review 8.  The tumour glyco-code as a novel immune checkpoint for immunotherapy.

Authors:  Ernesto RodrÍguez; Sjoerd T T Schetters; Yvette van Kooyk
Journal:  Nat Rev Immunol       Date:  2018-02-05       Impact factor: 53.106

Review 9.  Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense.

Authors:  Kayluz Frias Boligan; Circe Mesa; Luis Enrique Fernandez; Stephan von Gunten
Journal:  Cell Mol Life Sci       Date:  2014-12-07       Impact factor: 9.261

Review 10.  Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.

Authors:  Anne M Macpherson; Simon C Barry; Carmela Ricciardelli; Martin K Oehler
Journal:  J Clin Med       Date:  2020-09-14       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.